Researchers from the University of Aberdeen have discovered that ellorarxine, a new drug, may protect neurons from damage, offering potential new treatment in the future.

Amyotrophic lateral sclerosis (ALS), a disease that causes progressive muscle weakness and loss of motor function, has long lacked new and effective treatments.

The research team, based at the University of Aberdeen, investigated whether ellorarxine, a compound that mimics the activity of vitamin A and targets a specific brain pathway, could protect nerve cells from damage.

The drug’s effects were tested in lab conditions, both in cells and mice, that mimic the types of stress contributing to ALS, such as oxidative damage and protein misfolding.

Their findings suggest that ellorarxine could offer a way to slow down the damage caused by the disease but more research is needed before this can be confirmed.

Ellorarxine’s protective effects on nerve cells

The team tested ellorarxine in nerve cells exposed to different forms of stress, such as excitotoxicity (which involves nerve overstimulation) and proteostasis disruption (linked to protein build-up in cells).

They found that the drug significantly reduced cell death caused by these stresses.

Ellorarxine protects neurons by reducing protein aggregation, preventing oxidative damage, and reducing drag in forming stress granules structures implicated in ALS progression.

What this means for the future?

This research could lead to a new treatment for ALS patients, as the drug shows potential for protecting nerve cells from the type of damage that drives the disease.

However, more studies are needed to understand how ellorarxine works in humans and to assess its long-term safety and effectiveness. We’re interested to see further results from this research.

The researchers stress that while these lab results are promising, trials with patients with MND will be required to confirm its potential benefits.

The full paper is published in Frontiers of Neuroscience.

You can read about our other blogs, news stories, or research here.